Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
1.75B
Market cap1.75B
Price-Earnings ratio
-4.05
Price-Earnings ratio-4.05
Dividend yield
Dividend yield
Average volume
833.61K
Average volume833.61K
High today
$30.28
High today$30.28
Low today
$26.22
Low today$26.22
Open price
$29.09
Open price$29.09
Volume
1.43M
Volume1.43M
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

As of today, Agios(AGIO) shares are valued at $29.14. The company's market cap stands at 1.75B, with a P/E ratio of -4.05.

As of 2026-05-30, Agios(AGIO) stock has fluctuated between $26.22 and $30.28. The current price stands at $29.14, placing the stock +11.1% above today's low and -3.8% off the high.

Agios(AGIO) shares are trading with a volume of 1.43M, against a daily average of 833.61K.

During the past year, Agios(AGIO) stock moved between $22.24 at its lowest and $46.00 at its peak.

During the past year, Agios(AGIO) stock moved between $22.24 at its lowest and $46.00 at its peak.

AGIO News

TipRanks 1d
Agios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path

Agios Pharmaceuticals (AGIO) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analy...

TipRanks 1d
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $40 from $41 and keeps a Buy rating on the shares after the company announced tebapivat...

Simply Wall St 6d
Will EU Thalassemia Approval for PYRUKYND Redefine Agios Pharmaceuticals' Mitapivat-Centric Investment Narrative?

Earlier in May 2026, the European Commission granted marketing authorization for Agios Pharmaceuticals’ PYRUKYND (mitapivat) to treat anemia in adults with tran...

Will EU Thalassemia Approval for PYRUKYND Redefine Agios Pharmaceuticals' Mitapivat-Centric Investment Narrative?

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.